BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 18650519)

  • 1. Sorafenib in liver cancer--just the beginning.
    Roberts LR
    N Engl J Med; 2008 Jul; 359(4):420-2. PubMed ID: 18650519
    [No Abstract]   [Full Text] [Related]  

  • 2. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib in advanced hepatocellular carcinoma.
    Palmer DH
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib in advanced hepatocellular carcinoma.
    Copur MS
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065701
    [No Abstract]   [Full Text] [Related]  

  • 5. Sorafenib for liver cancer: the horizon broadens.
    Johnson P; Billingham L
    Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib in advanced hepatocellular carcinoma.
    Spinzi G; Paggi S
    N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
    [No Abstract]   [Full Text] [Related]  

  • 8. [Hepatocellular carcinoma - long-term treatable disease].
    FĂ­nek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 10. [Sorafenib in advanced hepatocellular carcinoma].
    Sauerbruch T; Gonzalez-Carmona AM; Nitschmann S
    Internist (Berl); 2009 Nov; 50(11):1290-2. PubMed ID: 19771405
    [No Abstract]   [Full Text] [Related]  

  • 11. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V; Barbare JC; Rosmorduc O;
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract]   [Full Text] [Related]  

  • 12. Speeding up cancer-drug development.
    Burton A
    Lancet Oncol; 2006 Oct; 7(10):798. PubMed ID: 17039633
    [No Abstract]   [Full Text] [Related]  

  • 13. 18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
    Siemerink EJ; Mulder NH; Brouwers AH; Hospers GA
    Oncologist; 2008 Jun; 13(6):734-5; author reply 736-7. PubMed ID: 18586929
    [No Abstract]   [Full Text] [Related]  

  • 14. Hepatocellular carcinoma: The beginning of a long journey.
    Cascinu S
    Dig Liver Dis; 2009 Oct; 41(10):707-8. PubMed ID: 19699696
    [No Abstract]   [Full Text] [Related]  

  • 15. Sorafenib.
    Rini BI
    Expert Opin Pharmacother; 2006 Mar; 7(4):453-61. PubMed ID: 16503817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hepatocellular carcinoma].
    Yamashita T; Arai K; Kaneko S
    Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
    Curtit E; Thiery-Vuillemin A; Nguyen T; Heyd B; Pivot X; Di Martino V; Borg C
    J Clin Oncol; 2011 Apr; 29(12):e330-2. PubMed ID: 21263091
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
    Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Sakata K; Matsugaki S; Kajiwara M; Fukuizumi K; Tajiri N; Matsukuma N; Sakai T; Ono N; Yano Y; Koga H; Kurogi J; Takata A; Sumie S; Satani M; Yamada S; Niizeki T; Aino H; Iwamoto H; Torimura T; Sata M
    Oncology; 2013; 84(2):108-14. PubMed ID: 23147476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
    Matsuda Y; Fukumoto M
    Med Mol Morphol; 2011 Dec; 44(4):183-9. PubMed ID: 22179180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma: sorafenib before liver transplantation?
    Braillon A
    Hepatology; 2010 Jun; 51(6):2232-3. PubMed ID: 20041410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.